Please login to the form below

Not currently logged in
Email:
Password:

Nimbus Therapeutics

This page shows the latest Nimbus Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Gilead chalks up trial success for new NASH drug

Gilead chalks up trial success for new NASH drug

Along with selonsertib, Gilead is also developing an FXR agonist called GS-9674 in phase I trials and acquired a wholly-owned subsidiary of Nimbus Therapeutics for $1.2bn earlier this ... Allergan has been building a pipeline of candidates through a

Latest news

  • Torrid times at Gilead lead to calls for a major M&A deal Torrid times at Gilead lead to calls for a major M&A deal

    The company has a history of making successful bolt-on acquisitions - adding its HIV blockbusters with the purchase of Triangle Therapeutics in 2003 and hepatitis portfolio by buying Pharmasset in 2011 - ... Smaller deals - including a $1.2bn deal for

  • FDA panel backs Intercept's rare liver disease drug FDA panel backs Intercept's rare liver disease drug

    As a NASH therapy Ocaliva could face competition from Gilead Sciences' simtuzumab (in phase II), an earlier stage acetyl-CoA carboxylase (ACC) inhibitor candidate just acquired from Nimbus Therapeutics, as well

  • Gilead boosts liver disease pipeline with $1.2bn acquisition Gilead boosts liver disease pipeline with $1.2bn acquisition

    Gilead Sciences boosted its pipeline of treatments for liver disease by buying a subsidiary of Nimbus Therapeutics in a deal that could be worth up to $1.2bn to the US ... In addition to the upfront payment of $400m, Nimbus Therapeutics also stands to

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest appointments

  • ARC names chairman and member of the board ARC names chairman and member of the board

    Iwicki is executive chairman of the board of directors of Kala Pharmaceuticals and sits on the boards of Nimbus Therapeutics and Taris Biomedical. ... He was president and CEO of Civitas Therapeutics until late 2014 and prior to this, held the same

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics